RT Journal Article
SR Electronic
T1 Blood-based multivariate methylation risk score for cognitive impairment and dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.27.23296143
DO 10.1101/2023.09.27.23296143
A1 Koetsier, Jarno
A1 Cavill, Rachel
A1 Reijnders, Rick
A1 Harvey, Joshua
A1 Deckers, Kay
A1 Köhler, Sebastian
A1 Eijssen, Lars
A1 Smith, Rebecca G.
A1 Smith, Adam R.
A1 Burrage, Joe
A1 Walker, Emma M.
A1 Shireby, Gemma
A1 Hannon, Eilis
A1 Dempster, Emma
A1 Frayling, Tim
A1 Mill, Jonathan
A1 Dobricic, Valerija
A1 Sommerer, Yasmine
A1 Johannsen, Peter
A1 Wittig, Michael
A1 Franke, Andre
A1 Vandenberghe, Rik
A1 Schaeverbeke, Jolien
A1 Freund-Levi, Yvonne
A1 Frölich, Lutz
A1 Scheltens, Philip
A1 Teunissen, Charlotte
A1 Frisoni, Giovanni
A1 Blin, Olivier
A1 Richardson, Jill
A1 Bordet, Régis
A1 Engelborghs, Sebastiaan
A1 de Roeck, Ellen
A1 Martinez-Lage, Pablo
A1 Tainta, Mikel
A1 Lleó, Alberto
A1 Sala, Isabel
A1 Popp, Julius
A1 Peyratout, Gwedoline
A1 Verhey, Frans
A1 Tsolaki, Magda
A1 Andreasson, Ulf
A1 Blennow, Kaj
A1 Zetterberg, Henrik
A1 Streffer, Johannes
A1 Vos, Stephanie J. B.
A1 Lovestone, Simon
A1 Visser, Pieter-Jelle
A1 Bertram, Lars
A1 Lunnon, Katie
A1 Pishva, Ehsan
YR 2023
UL http://medrxiv.org/content/early/2023/09/28/2023.09.27.23296143.abstract
AB INTRODUCTION Given the established association between DNA methylation and the pathophysiology of dementia and its plausible role as a molecular mediator of lifestyle and environment, blood-derived DNA methylation data could enable early detection of dementia risk.METHODS In conjunction with an extensive array of machine learning techniques, we employed whole blood genome-wide DNA methylation data as a surrogate for 14 modifiable and non-modifiable factors in the assessment of dementia risk in two independent cohorts of Alzheimer’s disease (AD) and Parkinson’s disease (PD).RESULTS We established a multivariate methylation risk score (MMRS) to identify the status of mild cognitive impairment (MCI) cross-sectionally, independent of age and sex. We further demonstrated significant predictive capability of this score for the prospective onset of cognitive decline in AD and PD.DISCUSSION Our work shows the potential of employing blood-derived DNA methylation data in the assessment of dementia risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported through a ZonMw Memorabel/Alzheimer Nederland Grant (733050516) to E.P. The current study was conducted as part of the EMIF-AD MBD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement number 115372, the resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution. The analysis of the DNA methylation data was in part funded by a major project grant from the Alzheimer's Society UK (AS-PG-14-038) to KL, a project grant from the Medical Research Council (MRC) (MR/N027973/1) to KL as part of the EPI-AD consortium through the Joint Programme-Neurodegenerative Disease Research (JPND) initiative. We thank all participants and teams who contributed data to PPMI. PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners including 4D Pharma, AbbVie, AcureX Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's (ASAP), Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb, Calico Life Sciences LLC, Celgene Corporation, DaCapo Brainscience, Denali Therapeutics, The Edmond J. Safra Foundation, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Pharmaceuticals, Lundbeck, Merck & Co., Meso Scale Diagnostics LLC, Neurocrine Biosciences, Pfizer, Piramal Imaging, Prevail Therapeutics, F. Hoffmann‐La Roche and its affiliated company Genentech, Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva Neuroscience, UCB, Vanqua Bio, Verily Life Sciences, Voyager Therapeutics and Yumanity Therapeutics. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://exetercrfnihr.org/about/exeter-10000-prb/ https://ida.loni.usc.edu/http://www.emif.eu/emif-ad-2/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorshttps://zenodo.org/record/8306113 Aβamyloid-βADAlzheimer’s diseaseADASAlzheimer’s disease assessment scaleAUROCarea under the receiver operating curveCIconfidence intervalCSFcerebral spinal fluidENElasticNetGOgene ontologyHRhazard ratioHWEHardy-Weinberg equilibriumLDELTOTALWechsler logical memory delayMAEmean absolute errorMAFminor allele frequencyMCImild cognitive impairmentsmQTLmethylation quantitative trait lociMMRSmultivariate methylation risk scoreMMSEMini Mental State ExaminationMPSmethylation profile scorePCAprincipal component analysisPDParkinson’s diseasePGSpolygenic (risk) scorep-tauphosphorylated tauQCquality controlRAVLTRey’s auditory verbal learning testRF-RFErandom forest with recursive feature eliminationSHAPShapley additive explanationsSNPsingle nucleotide polymorphismsPLS-DAsparse partial least squares discriminant analysisTRABSCORtrail making test part B timet-tautotal tauUTRuntranslated region.